Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology

Steven T. Bird(United States Food and Drug Administration), Abraham G. Hartzema(University of Florida), James M. Brophy(McGill University Health Centre), Joseph A. Delaney(Center for Drug Evaluation and Research), Sean Skeldon(University of British Columbia), Mahyar Etminan(Oncolytics Biotech (Canada))
BMJ
November 5, 2013
Cited by 86


Related Papers